The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Scots-knight Denise since 2005.
This trader's CIK number is 1297000.
At the time of last reporting, Scots-knight Denise was the Chief Executive Officer of Mereo Biopharma Group Plc. (stock ticker symbol MREO).
Also see all insider trading activities at Mereo Biopharma Group Plc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2005 | IDIX | 0 | $0 | 629,498 | $12,973,953 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | MREO | 0 | $0 | 221,642 | $844,903 | 470,150 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2014 | OMED | 0 | $0 | 175,499 | $3,994,780 | 0 | $0 |
| 2014 | OMED | 0 | $0 | 3,799 | $82,301 | 0 | $0 |
| 2013 | OMED | 58,824 | $1,000,008 | 0 | $0 | 0 | $0 |
1. Idenix Pharmaceuticals Inc (IDIX)
2. Mereo Biopharma Group Plc (MREO)
3. Oncomed Pharmaceuticals Inc (OMED)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2005-11-14 | IDIX | Sale | 629,498 | 20.61 | 12,973,953 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-09-13 | MREO | Sale | 60,046 | 4.22 | 253,454 |
| 2024-09-12 | MREO | Sale | 28,611 | 4.47 | 127,977 |
| 2024-09-11 | MREO | Option Ex | 188,060 | .00 | 0 |
| 2024-06-25 | MREO | Sale | 40,712 | 3.69 | 150,390 |
| 2024-06-26 | MREO | Sale | 92,273 | 3.39 | 313,082 |
| 2024-06-21 | MREO | Option Ex | 282,090 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2014-12-31 | OMED | Sale | 3,799 | 21.66 | 82,301 |
| 2014-12-26 | OMED | Sale | 2,195 | 21.65 | 47,517 |
| 2014-12-29 | OMED | Sale | 9,902 | 21.62 | 214,051 |
| 2014-12-30 | OMED | Sale | 5,510 | 21.65 | 119,285 |
| 2014-12-19 | OMED | Sale | 20,654 | 21.71 | 448,315 |
| 2014-12-08 | OMED | Sale | 1,727 | 21.68 | 37,434 |
| 2014-12-09 | OMED | Sale | 23,273 | 21.78 | 506,979 |
| 2014-12-10 | OMED | Sale | 7,940 | 21.77 | 172,885 |
| 2014-12-05 | OMED | Sale | 25,000 | 21.84 | 546,025 |
| 2014-06-30 | OMED | Sale | 11,485 | 23.59 | 270,919 |
| 2014-06-25 | OMED | Sale | 3,252 | 23.56 | 76,623 |
| 2014-06-23 | OMED | Sale | 52,797 | 24.20 | 1,277,423 |
| 2014-06-24 | OMED | Sale | 11,764 | 23.57 | 277,324 |
| 2013-07-23 | OMED | Buy | 58,824 | 17.00 | 1,000,008 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Scots-knight Denise (Chief Executive Officer of Mereo Biopharma Group Plc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.